BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...a Phase III trial in first-time living donor kidney transplant recipients.End of the road for Santhera’s...
...A DSMB said the Phase III SIDEROS trial was unlikely to meet its primary endpoint. Santhera...
...Puldysa (Brand) SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena (Other) Vir Biotechnology Inc. GlaxoSmithKline plc BioNTech SE Pfizer Inc. Santhera Pharmaceuticals Holding AG Alexion...
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...a June complete response letter for NASH candidate Ocaliva obeticholic acid (see “NASH Pipeline Still Full”).Santhera...
...rights to Duchenne muscular dystrophy therapy vamorolone from Idorsia Ltd. (SIX:IDIA) (see “Deal with Idorsia Gives Santhera...
...oca) Vamorolone (VBP15) Gilead Sciences Inc. Kite Pharma Inc. HiFiBiO Therapeutics Amarin Corp. plc Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals plc Intercept Pharmaceuticals Inc. Santhera Pharmaceuticals Holding AG Idorsia...
BioCentury | Apr 9, 2020
Finance

Wuhan gene therapy play Neurophth raises $18M series A

...a series B round by year-end to support U.S. and China clinical trials, said Xiao. Santhera Pharmaceuticals Holding AG...
BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...created position of COO and EVP, non-clinical and manufacturing operations. He was preclinical development director. Santhera Pharmaceuticals Holding AG...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...Biochem Inc. (NYSE:ENZ). BioCentury Staff Cognition Therapeutics Inc. Glympse Bio Inc. Imago BioSciences Inc. Kleo Pharmaceuticals Inc. Entrada Therapeutics Inc. Acadia Pharmaceuticals Inc. Santhera Pharmaceuticals Holding AG Aeglea...
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...time to stand test. Santhera gained CHF1.12 to CHF13.80 on the news. In November 2018, Santhera...
...of Actelion Ltd. (see "Deal With Idorsia Gives Santhera Shot at Second DMD Candidate" ). Santhera...
...submission could occur by YE20. Santhera CEO Thomas Meier previously told BioCentury vamorolone would complement Santhera's...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...America, a division of Roche (SIX:ROG; OTCQX:RHHBY) Christoph Rentsch will step down as CFO of Santhera...
...Associate Editor Accelerate Diagnostics Inc. Aravive Inc. Editas Medicine Inc. Emalex Biosciences Inc. JMP Securities Melinta Therapeutics Inc. Molecular Partners AG Palladio Biosciences Inc. Santhera Pharmaceuticals Holding AG TCR2...
BioCentury | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

...Phase II/III Data for Rare CNS Disorder Therapy" ). Santhera submits MAA for DMD therapy Santhera...
...idebenone to treat respiratory dysfunction in Duchenne muscular dystrophy patients who are not using glucocorticoids. Santhera...
...plc Celgene Corp. Fondazione Telethon Gedeon Richter plc Hansoh Pharmaceutical Group Co. Ltd. Juvenescence Ltd. Newron Pharmaceuticals S.p.A. Orchard Therapeutics plc Ospedale San Raffaele Santhera Pharmaceuticals Holding AG University...
BioCentury | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

...Chiesi gains rights to Santhera's Raxone for LHON Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy...
...and all other ophthalmological indications; the short-chain benzoquinone received EU approval for LHON in 2015. Santhera...
...Raxone (Other), Catena (Other) Broad Institute of MIT and Harvard Chiesi Farmaceutici S.p.A. Columbia University Dynavax Technologies Corp. InBios International Inc. Regeneron Santhera Pharmaceuticals Holding AG Syntonix...
BioCentury | Apr 12, 2019
Financial News

Santhera raises CHF7.1M in private placement

...a private placement and established a credit facility of up to CHF15 million ($15 million). Santhera Pharmaceuticals Holding AG...
...price on April 4, when it announced the financing. The placement agent was Mirabaud Securities. Santhera's...
...Staff Writer Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena (Other) Santhera Pharmaceuticals Holding AG Optic...
Items per page:
1 - 10 of 267
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...a Phase III trial in first-time living donor kidney transplant recipients.End of the road for Santhera’s...
...A DSMB said the Phase III SIDEROS trial was unlikely to meet its primary endpoint. Santhera...
...Puldysa (Brand) SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena (Other) Vir Biotechnology Inc. GlaxoSmithKline plc BioNTech SE Pfizer Inc. Santhera Pharmaceuticals Holding AG Alexion...
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...a June complete response letter for NASH candidate Ocaliva obeticholic acid (see “NASH Pipeline Still Full”).Santhera...
...rights to Duchenne muscular dystrophy therapy vamorolone from Idorsia Ltd. (SIX:IDIA) (see “Deal with Idorsia Gives Santhera...
...oca) Vamorolone (VBP15) Gilead Sciences Inc. Kite Pharma Inc. HiFiBiO Therapeutics Amarin Corp. plc Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals plc Intercept Pharmaceuticals Inc. Santhera Pharmaceuticals Holding AG Idorsia...
BioCentury | Apr 9, 2020
Finance

Wuhan gene therapy play Neurophth raises $18M series A

...a series B round by year-end to support U.S. and China clinical trials, said Xiao. Santhera Pharmaceuticals Holding AG...
BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...created position of COO and EVP, non-clinical and manufacturing operations. He was preclinical development director. Santhera Pharmaceuticals Holding AG...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...Biochem Inc. (NYSE:ENZ). BioCentury Staff Cognition Therapeutics Inc. Glympse Bio Inc. Imago BioSciences Inc. Kleo Pharmaceuticals Inc. Entrada Therapeutics Inc. Acadia Pharmaceuticals Inc. Santhera Pharmaceuticals Holding AG Aeglea...
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...time to stand test. Santhera gained CHF1.12 to CHF13.80 on the news. In November 2018, Santhera...
...of Actelion Ltd. (see "Deal With Idorsia Gives Santhera Shot at Second DMD Candidate" ). Santhera...
...submission could occur by YE20. Santhera CEO Thomas Meier previously told BioCentury vamorolone would complement Santhera's...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...America, a division of Roche (SIX:ROG; OTCQX:RHHBY) Christoph Rentsch will step down as CFO of Santhera...
...Associate Editor Accelerate Diagnostics Inc. Aravive Inc. Editas Medicine Inc. Emalex Biosciences Inc. JMP Securities Melinta Therapeutics Inc. Molecular Partners AG Palladio Biosciences Inc. Santhera Pharmaceuticals Holding AG TCR2...
BioCentury | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

...Phase II/III Data for Rare CNS Disorder Therapy" ). Santhera submits MAA for DMD therapy Santhera...
...idebenone to treat respiratory dysfunction in Duchenne muscular dystrophy patients who are not using glucocorticoids. Santhera...
...plc Celgene Corp. Fondazione Telethon Gedeon Richter plc Hansoh Pharmaceutical Group Co. Ltd. Juvenescence Ltd. Newron Pharmaceuticals S.p.A. Orchard Therapeutics plc Ospedale San Raffaele Santhera Pharmaceuticals Holding AG University...
BioCentury | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

...Chiesi gains rights to Santhera's Raxone for LHON Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy...
...and all other ophthalmological indications; the short-chain benzoquinone received EU approval for LHON in 2015. Santhera...
...Raxone (Other), Catena (Other) Broad Institute of MIT and Harvard Chiesi Farmaceutici S.p.A. Columbia University Dynavax Technologies Corp. InBios International Inc. Regeneron Santhera Pharmaceuticals Holding AG Syntonix...
BioCentury | Apr 12, 2019
Financial News

Santhera raises CHF7.1M in private placement

...a private placement and established a credit facility of up to CHF15 million ($15 million). Santhera Pharmaceuticals Holding AG...
...price on April 4, when it announced the financing. The placement agent was Mirabaud Securities. Santhera's...
...Staff Writer Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena (Other) Santhera Pharmaceuticals Holding AG Optic...
Items per page:
1 - 10 of 267